Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave

Core Insights - The integration of Artificial Intelligence (AI) is revolutionizing the biotechnology industry, enhancing drug discovery and other processes [1][3] - AI is now central to biotech innovation, creating significant opportunities for profitability and growth [3][4] - The biotechnology sector is projected to continue its growth trajectory, driven by demographic changes and healthcare demands [8] AI Integration in Biotechnology - AI has transitioned from peripheral use to being embedded in core processes such as target identification and clinical strategy, with approximately 75% of biotech firms integrating AI into their workflows [5][10] - Notable biotech firms leveraging AI include: - Gilead Sciences (GILD) focuses on AI-driven molecular modeling for oncology and infectious diseases [5] - Vertex Pharmaceuticals (VRTX) utilizes machine learning for gene-editing technologies [6] - Regeneron (REGN) employs AI to decode complex disease mutations [6] - Moderna (MRNA) optimizes mRNA sequences for personalized cancer vaccines [6] - The rapid adoption of AI is increasing the success rate of drug candidates while reducing R&D costs, leading to a more profitable pipeline [7] Investment Opportunities in Biotech ETFs - Biotech ETFs provide diversified exposure to the AI-driven growth in the biotechnology sector, allowing investors to benefit from successful firms while mitigating risks associated with individual stocks [11][12] - Key biotech ETFs include: - iShares Biotechnology ETF (IBB) with $8 billion in net assets, gaining 21.9% over the past year [13] - State Street SPDR S&P Biotech ETF (XBI) with $7.29 billion in net assets, soaring 38.5% over the past year [14] - VanEck Biotech ETF (BBH) with $7.29 billion in net assets, increasing 13.5% over the past year [15] - Global X Genomics & Biotechnology ETF (GNOM) with $47.4 million in net assets, rallying 22.1% over the past year [16][17]